NICE TAs

11/12/2025

TA1116: Obecabtagene autoleucel for treating relapsed or refractory B-cell precursor acute lymphoblastic leukaemia

10/12/2025

TA1115: Vutrisiran for treating transthyretin amyloidosis with cardiomyopathy

03/12/2025

TA1114: Talquetamab for treating relapsed and refractory multiple myeloma after 3 or more treatments

03/12/2025

TA1113: Glofitamab with gemcitabine and oxaliplatin for treating relapsed or refractory diffuse large B-cell lymphoma

19/11/2025

TA1110: Abiraterone (originator and generics) for treating newly diagnosed high-risk hormone‑sensitive metastatic prostate cancer

12/11/2025

TA1109: Darolutamide with androgen deprivation therapy for treating hormone-sensitive metastatic prostate cancer

05/11/2025

TA1107: Delgocitinib for treating moderate to severe chronic hand eczema

05/11/2025

TA1106: Cabotegravir for preventing HIV-1 in adults and young people

05/11/2025

TA1108: Cemiplimab with platinum-based chemotherapy for untreated advanced non-small-cell lung cancer

22/10/2025

TA1105: Clascoterone for treating acne vulgaris in people 12 years and over (terminated appraisal)

22/10/2025

TA1104: Sarilumab for treating polyarticular or oligoarticular juvenile idiopathic arthritis in people 2 to 17 years (terminated appraisal)

21/10/2025

TA1103: Lorlatinib for ALK-positive advanced non-small-cell lung cancer that has not been treated with an ALK inhibitor

08/10/2025

TA1101: Garadacimab for preventing recurrent attacks of hereditary angioedema in people 12 years and over

01/10/2025

TA1099: Durvalumab for treating limited-stage small-cell lung cancer after platinum-based chemoradiotherapy

24/09/2025

TA1098: Isatuximab in combination for untreated multiple myeloma when a stem cell transplant is unsuitable

11/09/2025

TA1097: Enfortumab vedotin with pembrolizumab for untreated unresectable or metastatic urothelial cancer when platinum-based chemotherapy is suitable

28/08/2025

TA1093: Idebenone for treating visual impairment in Leber's hereditary optic neuropathy in people 12 years and over

28/08/2025

TA1095: Guselkumab for previously treated moderately to severely active Crohn's disease

28/08/2025

TA1094: Guselkumab for treating moderately to severely active ulcerative colitis

27/08/2025

TA1092: Pembrolizumab with carboplatin and paclitaxel for untreated primary advanced or recurrent endometrial cancer